: AKAO

Achaogen Inc (NASDAQ: AKAO)

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections in the United States.

Achaogen Inc (NASDAQ: AKAO)

Achaogen, Inc. operates as a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections.